223 results on '"Hambly, Nathan"'
Search Results
2. BAL Fluid Cellular Analysis and Radiologic Patterns in Patients With Fibrotic Interstitial Lung Disease
3. The Clinical Frailty Scale for Risk Stratification in Patients With Fibrotic Interstitial Lung Disease
4. Characteristics and risk factors of interstitial pneumonia with autoimmune features
5. Integration and Application of Radiologic Patterns From Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis
6. Association Between the Pulmonary Artery Pulsatility Index and Prognosis in Pulmonary Arterial Hypertension: A Multicentre Study
7. Pulmonary hypertension and associated outcomes in noncardiac surgery: A systematic review and meta-analysis
8. Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease: A Multicenter Study
9. Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease
10. Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study
11. Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
12. Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis
13. Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic
14. Sputum quantitative cytometry in patients with interstitial lung disease and chronic cough
15. Impact of saline loading at cardiac catheterization on the classification and management of patients evaluated for pulmonary hypertension
16. Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi‐centre registry cohort
17. Lung imaging patterns in connective tissue disease–associated interstitial lung disease impact prognosis and immunosuppression response
18. Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease
19. Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis
20. Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease
21. Characteristics and risk factors of interstitial pneumonia with autoimmune features
22. The clinical frailty scale is associated with progression of fibrotic interstitial lung disease – a multicentre cohort study.
23. Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung Disease
24. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
25. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease
26. Treatment of rheumatoid arthritis-associated interstitial lung disease in a multi-center registry cohort
27. Myeloid‐specific deletion of activating transcription factor 6 alpha increases CD11b + macrophage subpopulations and aggravates lung fibrosis
28. Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions
29. Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
30. Chronic obstructive pulmonary disease
31. Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease
32. Myeloid‐specific deletion of activating transcription factor 6 alpha increases CD11b+ macrophage subpopulations and aggravates lung fibrosis.
33. Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease
34. Biomarkers in interstitial lung disease: moving towards composite indexes and multimarkers?
35. Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease
36. Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis
37. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry
38. Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease
39. Pulmonary hypertension: diagnostic approach and optimal management
40. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry
41. Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease
42. Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Non-IPF Fibrotic Interstitial Lung Disease
43. Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections
44. Molecular classification of idiopathic pulmonary fibrosis: Personalized medicine, genetics and biomarkers
45. Treatment Initiation in Patients with Interstitial Lung Disease in Canada
46. TRANSITIONING FROM PARENTERAL PROSTACYCLIN THERAPY TO ORAL SELEXIPAG IN PULMONARY ARTERIAL HYPERTENSION
47. Lasting changes to circulating leukocytes in people with mild SARS-CoV-2 infections
48. Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study
49. Additional file 1 of Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease
50. Clinical relevance of rheumatoid factor and anti‐citrullinated peptides in fibrotic interstitial lung disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.